Summary

There was no significant difference in 3-year disease-free survival in sequential treatment of paclitaxel and the oral fluoropyrimidine tegafur-uracil or paclitaxel and another fluoropyrimidine, S-1, in serosa-invading gastric cancer. This article presents data from the Adjuvant Paclitaxel Followed by Oral Fluorinated Pyrimidines for Locally Advanced Gastric Cancer trial [SAMIT; Yoshida K et al. J Clin Oncol 2013 (suppl; abstr LBA4002)].